Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958109 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
A Phase 1 study of Metabolic Diseases, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04958109 is a Phase 1 study of Metabolic Diseases that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 197-participant average among 12 other Metabolic Diseases trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04958109, a Phase 1 study of Metabolic Diseases, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
Conditions Studied
Interventions
- DRUG Placebo
- DIAGNOSTIC_TEST Oral Glucose Tolerance Test
- DRUG Kisspeptin
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958109
The ClinicalTrials.gov registry entry for NCT04958109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 12 other Metabolic Diseases trials with a reported enrollment target (92% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolic Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04958109 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04958109 about?
NCT04958109 is a clinical study titled "Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test". The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test
What is the current status of trial NCT04958109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-10-28. Estimated completion is 2022-10-31.
What conditions does trial NCT04958109 study?
This clinical trial studies the following conditions: Metabolic Diseases.
What interventions are being tested in trial NCT04958109?
The interventions under investigation include: Placebo (DRUG), Oral Glucose Tolerance Test (DIAGNOSTIC_TEST), Kisspeptin (DRUG).
Who is sponsoring clinical trial NCT04958109?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04958109 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
COMPLETED · Phase 1
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
Effects of HIIT vs. TRE on Type 2 Diabetes Risk
RECRUITING · NA
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
The Effect of Processing on Food Reward
RECRUITING · NA
-
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.